Cancer-related fatigue (CRF) and cancer-related cognitive impairment (CRCI) are among the
most commonly reported disabling symptoms experienced by patients with advanced cancer.
However, there are currently limited evidence-based pharmacologic interventions available.
The investigators will conduct a Vanguard Randomized Clinical Trial (RCT) to estimate the
effect of modafinil in managing CRF and CRCI, and to test the feasibility of carrying out the
study.